Acute reversal of anticoagulant-induced bleeding complications.
Crowther
Mark A
MA
McMaster University, Canada.
D000925:Anticoagulants / Q000009:adverse effects*; D000931:Antidotes / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use; D001596:Benzylamines / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004967:Estrogens / Q000627:therapeutic use; D005544:Forecasting; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D010949:Plasma; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D017713:Platelet Transfusion; D065227:Transfusion Reaction
D000925:Anticoagulants; D000931:Antidotes; D000933:Antifibrinolytic Agents; D001384:Azetidines; D001596:Benzylamines; D004967:Estrogens; D006490:Hemostatics; D010975:Platelet Aggregation Inhibitors; C426686:ximelagatran